
Gliomas remain refractory to contemporary neurosurgical and adjuvant therapies due to diffuse infiltration, immune evasion, and rapid development of therapeutic resistance. Extracellular vesicles (EVs), lipid-encapsulated substrates of various sizes that carry nucleic acid or proteins, are now recognized as central regulators of tumor–immune crosstalk and a potential unifying mechanism linking microenvironmental reprogramming with disease progression. Glioma-derived EVs function as active signaling platforms that remodel the tumor microenvironment. EV cargo—including PD-L1, TGF-β, and regulatory microRNAs—suppresses cytotoxic T-cell function, promotes M2 macrophage polarization, and impairs dendritic cell antigen presentation, collectively reinforcing an immunosuppressive niche. Additionally, EV-mediated transfer of resistance-associated cargo contributes to chemoresistance and radioresistance, representing key paracrine mechanisms of treatment failure. EV-associated nucleic acids specifically have enabled detection of alterations such as EGFRvIII, IDH1 mutations, and MGMT promoter methylation in early clinical studies. These findings support EV-based liquid biopsy as a promising approach for minimally invasive molecular characterization and disease monitoring. However, most mechanistic and therapeutic evidence remains preclinical, while clinical studies are limited by small cohorts, heterogeneous EV isolation and characterization methods, and a lack of prospective validation. Ultimately, EVs represent a biologically important interface between glioma biology and the immune microenvironment, with emerging applications in disease monitoring and therapeutic development. Prospective validation and technical standardization remain essential to enable clinical translation.
Satellite glial cells (SGCs) are specialized glial cells found in peripheral ganglia, including the dorsal root ganglia (DRG), where they tightly envelop sensory neuronal somata. Through this intimate bidirectional communication, SGCs actively regulate neuronal homeostasis and excitability and contribute to pain. This review discusses the physiological functions of SGCs in the DRG and the mechanisms underlying their contribution to pain across different conditions, as well as their neuroimmune and reparative roles and their potential as therapeutic targets. The literature reviewed indicates that SGCs contribute to neuronal homeostasis through structural and metabolic support and regulation of neuronal excitability. However, these functions can become altered under pathological conditions, involving changes in gap junction communication, purinergic and glutamatergic signaling, and inflammatory mediator production that are associated with SGC activation, neuronal sensitization and pain initiation and persistence. These alterations have been described across inflammatory, neuropathic, diabetic, chemotherapy-induced, and cancer-associated pain. Recent transcriptomic studies further indicate substantial SGC heterogeneity, suggesting distinct cellular states and functions and highlighting the importance of associated markers for their characterization. Beyond pain, SGCs participate in neuroimmune interactions, immune-related responses, and neuronal repair within the DRG microenvironment. Experimental interventions targeting SGC-associated pathways, including nutraceuticals, have produced analgesic effects in several preclinical models. Overall, SGCs are multifunctional components of the DRG, spanning physiological neuronal support and homeostasis to pathological pain and neuroimmune responses. Further investigation of SGC heterogeneity, functional states, and associated pathways may clarify their contribution to pain and support the development of SGC-associated therapeutic strategies for pain management.
Background/Objectives: Oligodendrocyte maturation and function are stimulated by insulin and insulin-like growth factor (IGF) signaling through Akt-mTOR and Notch. Dysregulation of these pathways is associated with impaired white matter development; yet, treatment with insulin-sensitizing agents failed to restore oligodendrocyte function, leading to the hypothesis that additional signaling pathways are needed for oligodendrocyte function. Methods: Experiments were conducted using human MO3.13 cells to investigate the role of epidermal growth factor receptor (EGFR) expression and signaling as potential mediators of immature oligodendroglia function and mechanistic interactions with insulin/IGF and Notch pathways. Methodologies included cell function, cytomorphology, immunoassays, and RNA hybridization assays. Results: Although EGF, TGF-α, and TGF-β increased the relative levels of EGFR tyrosine phosphorylation (pY-EGFR), MTT activity, and proliferating cell nuclear antigen, EGF and TGF-β increased pY-Erk MAPK and GALC expression and reduced activated Caspase 3, while EGF selectively increased CNPase, MAG, MOG, and MBP. EGF and TGF-α stimulated IGF2, INSULINR, IGF1R, IGF2R, IRS1, and IRS2 mRNA transcripts, while TGF-α and TGF-β increased expression of NOTCH1, JAGGED1, HES1, HEY1, and HIF1A Notch network genes. Conclusions: EGF, TGF-α, and TGF-β differentially modulated the effects of EGFR stimulation on oligodendroglia-related functions, including protein expression. The findings highlight the potential importance of EGFR pathway signaling and its interactions with insulin/IGF and Notch pathways for regulating oligodendrocyte functions during development.
Experience-dependent plasticity involves coordinated changes in neuronal and glial function, but the glial contribution to circuit adaptation in autism spectrum disorder (ASD) remains incompletely understood. Astrocytes monitor synaptic activity and metabolic demand, microglia participate in activity-dependent synaptic remodeling, and oligodendrocyte-lineage cells adjust differentiation and myelination in response to neuronal firing and learning. Human induced pluripotent stem cell models, xenotransplantation studies, postmortem single-cell datasets and genetic models implicate these cells in ASD-associated circuit dysfunction, with causal contributions having been demonstrated for defined phenotypes in experimental systems. In this narrative review, we integrate this evidence with studies of sensory stimulation and deprivation, motor learning and social experience to examine how glia may link repeated activity with durable circuit adaptation. Motor-skill learning requires rapid oligodendrocyte production, whereas juvenile social experience regulates prefrontal oligodendrocyte maturation. Visual stimulation evokes astrocytic Ca2+ responses, and voluntary exercise can restore microglial engulfment of excess synapses in a maternal-immune-activation model. Environmental enrichment includes direct and perturbation-based glial evidence, whereas music provides predominantly associative or cell-nonspecific observations. Fragile X studies connect astrocytic dysfunction with motor learning and sensory responses, but the involvement of glia varies with genotype, circuit and developmental stage. The evidence nevertheless differs substantially across systems. Cell-specific causality has been demonstrated for selected astrocytic, microglial and oligodendroglial mechanisms, whereas human intervention studies remain largely cell-nonspecific. Taken together, these findings support glial participation in experience-dependent plasticity but do not establish glial mediation of human interventions. ASD-associated glial states may therefore modify the response to experience, rather than representing targets whose normalization can be assumed to be beneficial.
Background/Objectives: Glioblastoma (GBM) is a highly aggressive brain tumor characterized by marked heterogeneity, therapy resistance, and poor prognosis. Dysregulation of autophagy and apoptosis may contribute to tumor adaptation, yet experimental GBM models differ in their translational relevance. This study compared model-dependent expression patterns of selected autophagy- and apoptosis-related genes and evaluated their patient-level relevance in TCGA-GBM. Methods: Relative expression of p62/SQSTM1, ATG7, BAX, and BCL2 was assessed descriptively across SVG p12, U87-MG, U87-MG spheroids, and U87-MG CD133+ using RT-qPCR-derived fold-change values. Experimental profiles were integrated with TCGA-GBM transcriptomic and clinical data using Cox proportional hazards regression and Spearman correlation analysis. Results: U87-MG showed upregulation of p62/SQSTM1, BAX, and BCL2 with modest ATG7 downregulation. U87-MG CD133+ showed reduced BAX, ATG7, and BCL2 expression despite retained p62/SQSTM1 upregulation, whereas spheroids displayed marked BAX upregulation together with reduced ATG7 and BCL2 expression. In the final TCGA-GBM cohort (n = 281), none of the four genes was significantly associated with overall survival in univariable, age- and sex-adjusted, or radiotherapy-stratified Cox models. Exploratory treatment-complete sensitivity analyses did not materially alter these findings. Gene–gene correlations were weak to moderate. Conclusions: GBM model selection substantially influences observed autophagy- and apoptosis-related transcriptional patterns. Limited concordance between experimental expression changes and patient-level survival associations indicates that these mRNA-level findings are hypothesis-generating rather than evidence of validated prognostic biomarkers and require a broader pathway, protein-level, and functional validation.